Welcome to AstraZeneca United States
Beginning its journey in 1953, AstraZeneca became one of the first pharmaceutical companies operating in the United States
Latest News from AstraZeneca United States
AstraZeneca purchases US manufacturing facility to support biologics manufacturing capabilities
AstraZeneca today announced that it has purchased a biologics manufacturing facility in Longmont, Colorado from Amgen Inc. This facility will be used to support AstraZeneca’s existing operations at its nearby Boulder site also purchased from Amgen in September of 2015.
Fulvestrant demonstrates progression-free survival advantage in 1st line advanced breast cancer
AstraZeneca today announced data from the Phase III FALCON trial demonstrating superior median progression-free survival (PFS) for fulvestrant 500mg compared to anastrozole 1mg in the 1st line treatment of postmenopausal women with locally-advanced or metastatic breast cancer, who have not had prior hormonal treatment for hormone receptor positive (HR+) breast cancer.
New study shows increases in RSV hospitalization among high-risk preterm infants
AstraZeneca today announced new data demonstrating that respiratory syncytial virus hospitalization (RSVH) rates increased significantly during the 2014-2015 RSV season among US infants <3 months of age born at 29-34 weeks gestational age (wGA), as compared to the 2013-2014 season.
US FDA approves TAGRISSO® (osimertinib) blood-based T790M companion diagnostic test
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved a blood-based companion diagnostic for TAGRISSO® (osimertinib). The companion diagnostic for TAGRISSO is the only FDA-approved and clinically validated companion diagnostic test that uses either tissue or a blood sample to confirm the presence of a T790M mutation in patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC), who have progressed on or after an EGFR tyrosine kinase inhibitor (TKI) medicine.
Latest AZ&You Blog Articles
Navigating Cancer Clinical Trials: Where to Start
When patients are diagnosed with cancer, the following questions may be top of mind as they begin their treatment journey: Should I consider joining a clinical trial? What does clinical trial participation entail? How can I locate the most appropriate clinical trial for my particular disease? How do I actually enroll in a clinical trial?
One Brave Idea $75 Million Research Award for Coronary Heart Disease Winner Announced
AstraZeneca, the American Heart Association (AHA) and Verily (formerly Google Life Sciences) announced Wednesday that Dr. Calum MacRae is the recipient of a $75 million research award to study coronary heart disease (CHD) and its consequences.
18 Years Strong: Living with Metastatic Breast Cancer
When doctors diagnosed Kristin Johnson St. Goddard with metastatic breast cancer, she was given 18 months to live. Fast forward 18 years and different treatment regimens - Kristin is still going strong. While some days are challenging, she continues to lead a good life, and remains hopeful that one day, there will be a cure. See her story.
New Resource Offers 24/7 Support for those with Mental Illness
Nine years ago, Danei Edelen was established in her career as a marketing executive and happily raising a family with her husband in Ohio. Then something unexpected happened. “After five nights of no sleep, hallucinations, I sought hospitalization,” Danei said. She subsequently learned she had experienced a psychotic break caused by an underlying and undiagnosed mental illness called bipolar disorder.
The Power of Diversity Celebrated at AstraZeneca’s 5th Annual Women’s Summit
“Leadership is surrounding yourself with others who do not think like you and bringing out the best in those people.”
“Fostering diversity does not need justification; it is simply the right thing to do.”
“Diversity fuels innovation; a team needs individuals who approach challenges differently.”
These messages were among those heard by hundreds of our employees last month at the 5th Annual Women’s Summit held on our Gaithersburg campus.
Connecting the Dots of Hereditary Cancer
By Sue Friedman, DVM, founder and Executive Director, Facing Our Risk of Cancer Empowered (FORCE)
In 1996, at the age of 33, I was diagnosed with breast cancer. My diagnosis came out of the blue. I was otherwise healthy, and only one relative, my grandmother, in my small family tree had also had cancer. My doctors didn’t appreciate how significant that one relative could be, and my health care team didn’t mention genetic testing. I had no idea that my cancer could be hereditary.
If you are passionate about science, these stories will show you how the latest and most exciting projects we have been working on and the people behind them.